WALTHAM, Mass • 2024-03-26

BostonGene Recognized as Designated Laboratory for the ComboMATCH Precision Medicine Clinical Trial

5 min to read

BostonGene’s Next-Generation Sequencing Assays Identify Patient Candidates for Biomarker-Driven ComboMATCH Trial
BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory. ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial. ComboMATCH aims to overcome drug resistance to single-drug therapies by developing targeted drug combinations. NCI is a part of the National Institutes of Health.

A unique initiative to test new combinations of cancer drugs guided by tumor biology, ComboMATCH aims to pair patients with locally advanced or advanced solid tumors with a therapy that has the potential to manage their cancer. The study will also assist physicians in devising more effective treatment strategies. ComboMATCH is led by the ECOG-ACRIN Cancer Research Group and the NCI through the National Clinical Trials Network (NCTN). ComboMATCH treatment trials are conducted by the NCTN research groups in the United States. These include the Alliance for Clinical Trials in Oncology, Children’s Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network. To learn more about ComboMATCH, visit https://ecog-acrin.org/combomatch and https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/combomatch.

Individuals with cancer being seen at participating clinical sites will enroll in the ComboMATCH registration trial through their oncologist to have their eligibility determined. ComboMATCH relies on standard tumor testing with next-generation sequencing (NGS) by a network of designated labs to identify any existing genetic alterations. Assignment to a treatment trial is based on actionable genetic alterations along with clinical factors, and the goal is to determine the effectiveness of treating cancer with a combination of targeted medications. Already a CAP-accredited and CLIA-certified lab, BostonGene will now serve as a designated NGS laboratory for ComboMATCH.

The BostonGene Tumor Portrait™ test uses DNA whole exome (WES) and RNA transcriptome (RNA-seq) sequencing to detect genomic alterations such as single nucleotide variants, insertions and deletions, copy number alterations, tumor mutational burden, microsatellite instability, fusions, frameshifts, cellular composition of malignant and tumor microenvironment compartments, and expression levels of more than 20,000 genes. In parallel, BostonGene partners with oncologists at leading cancer centers and biopharma companies to discover, validate, and translate molecular biomarkers of therapeutic response from bench to bedside.

“Our participation in the ComboMATCH trials underscores our commitment to advancing precision cancer medicine,” says Nathan Fowler, MD, Chief Medical Officer at BostonGene. “Our mission is to unravel the complex molecular landscape of cancer, leveraging data-driven insights to improve treatment strategies."

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene offers customized client solutions using a multi-omic approach prioritized for real-world impact, optimizing standard-of-care therapies, accelerating research and delivering cost-effective, measurable data-driven results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth analysis of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies and recommended treatments. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director